Eli Lilly Reports Strong Q1 Results and Raises Full-Year Outlook Due to GLP-1 Sales Growth
Eli Lilly and Co (LLY) reported first-quarter 2026 results that exceeded expectations, driven by strong sales of its GLP-1 treatments Mounjaro and Zepbound. The company raised its full-year revenue and EPS guidance, citing continued regulatory and pipeline momentum.
Tickers: $LLY
Topics: Drug Approvals Earnings GLP-1 Sales M&A Activity Pipeline Updates Revenue Growth